Mario Francisco Guerrero *

Autor invitado por SIIC

El trabajo contribuye a plantear el efecto antihipertensivo de la especie Passiflora quadrangularis

PASSIFLORA QUADRANGULARIS PREVIENE LA HIPERTENSIÓN EXPERIMENTAL

El extracto de la parte aérea de Passiflora quadrangularis (N.V. badea) previene la hipertensión experimental inducida por déficit de óxido nítrico en ratas de laboratorio, mejora la respuesta del endotelio vascular y disminuye el remodelado vascular.

*Mario Francisco Guerrero
describe para SIIC los aspectos relevantes de su trabajo
PASSIFLORA QUADRANGULARIS L. PREVIENE LA HIPERTENSIÓN EXPERIMENTAL Y EL REMODELADO VASCULAR EN RATAS EXPUESTAS A DÉFICIT DE ÓXIDO NÍTRICO
Institución principal de la investigación
*Universidad Nacional de Colombia, Sede Bogotá, Bogotá, Colombia
Imprimir nota

Comprar este artículo
Otros artículos escogidos

Referencias bibliográficas
1. Poulter NR, Prabhakaran D, Caulfield M. Hypertension. Lancet 386(9995):801-12, 2015.
2. Sarki AM, Nduka CU, Stranges S, Kandala NB, Uthman OA. Prevalence of hypertension in low- and middle-income countries. Medicine 94(50):e1959, 2015.
3. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries. Circulation 134(6):441-50, 2016.
4. Lobo MD, Sobotka PA, Pathak A. Interventional procedures and future drug therapy for hypertension. Eur Heart J 38(15):ehw303, 2016.
5. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc 86(4):304-14, 2011.
6. Cragg GM, Newman DJ. Natural products: A continuing source of novel drug leads. Biochim Biophys Acta - Gen Subj 1830(6):3670-95, 2013.
7. Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. In: Li EC, editor. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2014
8. Wiysonge CS, Opie LH. B-Blockers as initial therapy for hypertension. JAMA 310(17):1851, 2013.
9. Moser M. Relative efficacy of, and some adverse reactions to, different antihypertensive regimens. Am J Cardiol 63(4):2B-7B, 1989.
10. Kehat I, Molkentin JD. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 122(25):2727-35, 2010.
11. Mayet J, Hughes A. Cardiac and vascular pathophysiology in hypertension. Heart 89(9):1104-9, 2003.
12. Ferrario CM. Cardiac remodelling and RAS inhibition. Ther Adv Cardiovasc Dis 10(3):162-71, 2016.
13. Elahi MM, Naseem KM, Matata BM. Nitric oxide in blood. The nitrosative-oxidative disequilibrium hypothesis on the pathogenesis of cardiovascular disease. FEBS J. 274(4):906-23, 2007.
14. Gkaliagkousi E, Gavriilaki E, Triantafyllou A, Douma S. Clinical significance of endothelial dysfunction in essential hypertension. Curr Hypertens Rep 17(11), 2015.
15. Sinha N, Dabla PK. Oxidative stress and antioxidants in hypertension-a current review. Curr Hypertens Rev 11(2):132-42, 2015.
16. Bleakley C, Hamilton PK, Pumb R, Harbinson M, McVeigh GE. Endothelial function in hypertension: victim or culprit? J Clin Hypertens 17(8):651-4, 2015.
17. Steven S, Münzel T, Daiber A. Exploiting the pleiotropic antioxidant effects of established drugs in cardiovascular disease. Int J Mol Sci 16(8):18185-223, 2015.
18. Ingale AG, Hivrale AU. Pharmacological studies of Passiflora sp. and their bioactive compounds. African J Plant Sci 4(10):417-26, 2010.
19. Ichimura T, Yamanaka A, Ichiba T, Toyokawa T, Kamada Y, Tamamura T, et al. Antihypertensive effect of an extract of Passiflora edulis rind in spontaneously hypertensive rats. Biosci Biotechnol Biochem 70(3):718-21, 2006.
20. Konta EM, Almeida MR, Do Amaral CL, Darin JDC, De Rosso VV, Mercadante AZ, et al. Evaluation of the antihypertensive properties of yellow passion fruit pulp (Passiflora edulis Sims f. flavicarpa Deg.) in spontaneously hypertensive rats. Phytother Res 28(1):28-32, 2014.
21. Lewis BJ, Herrlinger KA, Craig TA, Mehring-Franklin CE, DeFreitas Z, Hinojosa-Laborde C. Antihypertensive effect of passion fruit peel extract and its major bioactive components following acute supplementation in spontaneously hypertensive rats. J Nutr Biochem 24(7):1359-66, 2013.
22. Patel SS, Verma NK, Shrestha B, Gauthaman K. Antihypertensive effect of methanolic extract of Passiflora nepalensis. Rev Bras Farmacogn 21(1):187-9, 2011.
23. Birudu RB, Naik JM, Janardhan M. Cardio protective activity of Passiflora foetida extract and silver nanoparticles in doxorubicin induced cardiac disease in rats. Indian J Res Pharm Biotechnol 3(5):329-34, 2015.
24. Appel K, Rose T, Fiebich B, Kammler T, Hoffmann C, Weiss G. Modulation of the G-aminobutyric acid (GABA) system by Passiflora incarnata L. Phytother Res 25(6):838-43, 2011.
25. Marín MM, Caetano CM, Posada Tique CA. Caracterización morfológica de especies del género Passiflora. Acta Agronómica 58:1-9, 2009.
26. Ocampo J. Diversity and distribution of Passifloraceae in the department of Huila in Colombia. Vol. 18, Acta Biológica Colombiana. Universidad Nacional de Colombia, Facultad de Ciencias, Departamento de Biología pp. 511-516, 2013.
27. Duque BC, Morales PAL. El aroma frutal de Colombia. Universidad Nacional de Colombia, Facultad de Ciencias, Departamento de Química 345 p, 2005.
28. Sanabria Galindo A. Analisis fitoquímico preliminar: metodología y su aplicación en la evaluación de 40 plantas de la familia Compositae. 1983.
29. Zibadi S, Farid R, Moriguchi S, Lu Y, Foo LY, Tehrani PM, et al. Oral administration of purple passion fruit peel extract attenuates blood pressure in female spontaneously hypertensive rats and humans. Nutr Res 27(7):408-16, 2007.
30. Beery AK, Zucker I. Sex bias in neuroscience and biomedical research. Neurosci Biobehav Rev 35(3):565-72, 2011.
31. Van Vliet BN, Chafe LL, Antic V, Schnyder-Candrian S, Montani JP. Direct and indirect methods used to study arterial blood pressure. J Pharmacol Toxicol Methods 44(2):361-73, 2000.
32. Sánchez D, Kassan M, Contreras MM, Carrón R, Recio I, Montero MJ, et al. Long-term intake of a milk casein hydrolysate attenuates the development of hypertension and involves cardiovascular benefits. Pharmacol Res 63(5):398-404, 2011.
33. Páez MT, Catalina Rodríguez D, López DF, Castañeda JA, Buitrago DM, Cuca LE, et al. Croton schiedeanus Schltd prevents experimental hypertension in rats induced by nitric oxide deficit. Brazilian J Pharm Sci. 2013.
34. Gómez-Roso M, Montero M, Carrón R, Sevilla M. Cardiovascular changes in spontaneously hypertensive rats are improved by chronic treatment with zofenopril. Br J Pharmacol 158(8):1911-21, 2009.
35. Yang HY, Yang SC, Chen ST, Chen JR. Soy protein hydrolysate ameliorates cardiovascular remodeling in rats with L-NAME-induced hypertension. J Nutr Biochem 19(12):833-9, 2008.
36. Bernátová I, Pechánová O, Kristek F. Mechanism of structural remodelling of the rat aorta during long-term NG-nitro-L-arginine methyl ester treatment. Jpn J Pharmacol 81(1):99-106, 1999.
37. Guerrero EI, Ardanaz N, Sevilla MA, Arévalo MA, Montero MJ. Cardiovascular effects of nebivolol in spontaneously hypertensive rats persist after treatment withdrawal. J Hypertens 24(1):151-8, 2006.
38. Gibbons GH. Endothelial function as a determinant of vascular function and structure: A new therapeutic target. Am J Cardiol 79(5):3-8, 1997.
39. Von Lueder TG, Krum H. RAAS inhibitors and cardiovascular protection in large scale trials. Cardiovasc Drugs Ther 27(2):171-9, 2013.
40. Augustyniak RA, Thomas GD, Victor RG, Zhang W. Nitric oxide pathway as new drug targets for refractory hypertension. Curr Pharm Des 11(25):3307-15, 2005.
41. Paulis L, Zicha J, Kunes J, Hojna S, Behuliak M, Celec P, et al. Regression of L-NAME-induced hypertension: the role of nitric oxide and endothelium-derived constricting factor. Hypertens Res 31(4):793-803, 2008.
42. Bernátová I, Pechánová O, Simko F. Effect of captopril in L-NAME-induced hypertension on the rat myocardium, aorta, brain and kidney. Exp Physiol 84(6):1095-105, 1999.
43. De Gennaro Colonna V, Rigamonti A, Fioretti S, Bonomo S, Manfredi B, Ferrario P, et al. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in l-NAME-induced hypertensive rats. Eur J Pharmacol 516(3):253-9, 2005.
44. Dhein S, Salameh A, Berkels R, Klaus W. Dual mode of action of dihydropyridine calcium antagonists: a role for nitric oxide. Drugs 58(3):397-404, 1999.
45. Simko F, Matúsková J, Lupták I, Pincíková T, Krajcírovicová K, Stvrtina S, et al. Spironolactone differently influences remodeling of the left ventricle and aorta in L-NAME-induced hypertension. Physiol Res 56 Suppl 2:S25-32, 2007.
46. Moningka NC, Tsarova T, Sasser JM, Baylis C. Protective actions of nebivolol on chronic nitric oxide synthase inhibition-induced hypertension and chronic kidney disease in the rat: a comparison with angiotensin II receptor blockade. Nephrol Dial Transplant 27(3):913-20, 2012.
47. Bryant CE, Allcock GH, Warner TD. Comparison of effects of chronic and acute administration of NG-nitro-L-arginine methyl ester to the rat on inhibition of nitric oxide-mediated responses. Br J Pharmacol 114(8):1673-9, 1995.
48. Landmesser U, Wollert KC, Drexler H. Potential novel pharmacological therapies for myocardial remodelling. Cardiovasc Res 81(3):519-27, 2008.
49. Heusch G, Libby P, Gersh B, Yellon D, Böhm M, Lopaschuk G, et al. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet 383(9932):1933-43, 2014.
50. Cameron AC, Lang NN, Touyz RM. Drug treatment of hypertension: focus on vascular health. Drugs 76(16):1529-50, 2016.
51. Simko F, Pechanova O. Remodelling of the heart and vessels in experimental hypertension: advances in protection. J Hypertens 28 Suppl 1(Suppl 1):S1-6, 2010.
52. Tucker EJ, Ledingham JM, Zheng Y, Laverty R. Effects of chronic inhibition of nitric oxide synthase in the genetically hypertensive rat. Clin Exp Pharmacol Physiol 27(8):647-9, 2000.
53. Arnal JF, Warin L, Michel JB. Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J Clin Invest 90(2):647-52, 1992.
54. Kopincová J, Púzserová A, Bernátová I. L-NAME in the cardiovascular system - nitric oxide synthase activator? Pharmacol Rep 64(3):511-20, 2012.
55, Skogastierna C, Luksha L, Kublickiene K, Eliasson E, Rane A, Ekström L. Beneficial vasoactive endothelial effects of fluvastatin: focus on prostacyclin and nitric oxide. Heart Vessels 26(6):628-36, 2011.
56. Nippon M. Angiotensin converting enzyme and aldosereductase inhibitory agent comprises Passiflora quadrangularis extract with organic solvent, water or vitexin. 1995-009562, p. 2, 1993.
57. Sui H, Yu Q, Zhi Y, Geng G, Liu H, Xu H. Effects of apigenin on the expression of angiotensin-converting enzyme 2 in kidney in spontaneously hypertensive rats. Wei Sheng Yan Jiu 39(6):693-6, 700, 2010.
58. Ramaiya SD, Bujang JS, Zakaria MH. Assessment of total phenolic, antioxidant, and antibacterial activities of Passiflora species. Scientific World Journal 2014:167309, 2014.
59. De Castro PCF, Hoshino A, Da Silva JC, Mendes FR. Possible anxiolytic effect of two extracts of Passiflora quadrangularis L. in experimental models. Phytother Res 21(5):481-4, 2007.
60. Gazola AC, Costa GM, Castellanos L, Ramos FA, Reginatto FH, Lima TCM, et al. Involvement of gabaergic pathway in the sedative activity of apigenin, the main flavonoid from Passiflora quadrangularis pericarp. Rev Bras Farmacogn 25(2):158-63, 2015.
61. Avula B, Wang YH, Rumalla C, Smillie TJ, Khan IA. Simultaneous determination of alkaloids and flavonoids from aerial parts os Passiflora species and dietary supplements using UPLC-UV-MS and HPTLC. Natural Prod Commun 7:1177-80, 2012.
62. Zucolotto SM, Fagundes C, Reginatto FH, Ramos FA, Castellanos L, Duque C, et al. Analysis of C-glycosyl flavonoids from South American Passiflora species by HPLC-DAD and HPLC-MS. Phytochem Anal 23(3):232-9, 2012.
63. Costa GM, Gazola AC, Zucolotto SM, Castellanos L, Ramos FA, Reginatto FH, et al. Chemical profiles of traditional preparations of four South American Passiflora species by chromatographic and capillary electrophoretic techniques. Rev Bras Farmacogn 26(4):451-8, 2016.
64. Orsini F, Pelizzoni F, Verotta L. Quadranguloside, a cycloartane triterpene glycoside from Passiflora quadrangularis. Phytochemistry 25(1):191-3, 1985.

Otros artículos de Mario Francisco Guerrero

Olaya MDP, Vergel NE, López JL, Viña MD, Guerrero MF. Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent. Biomedica 39(3):491-501, 2019.
Vergel NE, López JL, Orallo F, Viña D, Buitrago DM, del Olmo E, Mico JA, Guerrero MF. Antidepressant-like profile and MAO-A inhibitory activity of 4-propyl-2H-benzo[h]-chromen-2-one. Life Sci 86(21-22):819-24, 2010.
Guerrero MF. Elements for the effective evaluation of natural products with possible antihypertensive effects. Biomedica 29(4):547-57, 2009.
Giraldo SE, Rincón J, Puebla P, Marder M, Wasowski C, Vergel N, Guerrero MF. Isovaleramide, an anticonvulsant molecule isolated from Valeriana pavonii. Biomedica 30(2):245-50, 2010.
Guerrero MF, Puebla P, Martín ML, Carrón R, San Román L, Reguero MT, Arteaga L. Inhibitory effect of N(G)-nitro-L-arginine methyl ester on the anti-adrenergic response elicited by ayanin in the pithed rat. Planta Med 68(4):322-5, 2002. doi: 10.1055/s-2002-26755.
Guerrero MF, Carrón R, Martín ML, San Román L, Reguero MT. Antihypertensive and vasorelaxant effects of aqueous extract from Croton schiedeanus Schlecht in rats. J Ethnopharmacol 75(1):33-6, 2001.
Guerrero MF, Puebla P, Carrón R, Martín ML, Arteaga L, Román LS. J Assessment of the antihypertensive and vasodilator effects of ethanolic extracts of some Colombian medicinal plants. Ethnopharmacol 80(1):37-42, 2002.
Guerrero MF, Puebla P, Carrón R, Martín ML, San Román L. Quercetin 3,7-dimethyl ether: a vasorelaxant flavonoid isolated from Croton schiedeanus Schlecht. J Pharm Pharmacol 54(10):1373-8, 2002.
Puebla P, Correa SX, Guerrero M, Carron R, San Feliciano A. New cis-clerodane diterpenoids from Croton schiedeanus. Chem Pharm Bull (Tokyo) 53(3):328-9, 2005.
Bareño LL, Puebla P, San Feliciano A, Guerrero MF. Vascular mechanisms of monodesmosidic triterpene saponins isolated from Passiflora quadrangularis L. Vitae 27(2):id-341585, 2020.

Para comunicarse con Mario Francisco Guerrero mencionar a SIIC como referencia:
mfguerrerop@unal.edu.co

---

Acerca del trabajo completo

PASSIFLORA QUADRANGULARIS PREVIENE LA HIPERTENSIÓN EXPERIMENTAL

Título original en castellano
PASSIFLORA QUADRANGULARIS L. PREVIENE LA HIPERTENSION EXPERIMENTAL Y EL REMODELADO VASCULAR EN RATAS EXPUESTAS A DEFICIT DE OXIDO NITRICO

Autores
Lesly Lizeth Bareño Ariza¹, Pilar Puebla Ibáñez², Gustavo Isaza³, Arturo San Feliciano⁴
1 Licenciada en Química, Universidad Nacional de Colombia, Sede Bogotá, Doctoranda en Ciencias Farmacéuticas
2 Química Farmacéutica, Universidad de Salamanca, Salamanca, España, Profesora Titular
3 Médico, Universidad de Caldas, Manizales, Colombia, Profesor Titular
4 Químico, Universidad de Salamanca, Salamanca, España, Profesor Catedrático

Acceso a la fuente original
Vitae - Revista de la Facultad de Ciencias Farmacéuticas y Alimentarias
http://aprendeenlinea.udea.edu.co/revistas/index.php/vitae

El artículo se relaciona estrictamente con las especialidades de siicsalud
El artículo se conecta secundariamente con las especialidades